Citius Pharmaceuticals Inc CTXR 深 滬
已收盤 05-08 16:00:00 美东时间
0.64
-0.014
-2.16%
華盛通- 最 高0.6609
- 今 開0.66
- 成交量 86.25万股
- 最 低 0.62
- 昨 收 0.6541
- 總市值 1.76万
- 52周最高 2.48
- 市盈率 靜 --
- 換手率 3141.91%
- 52周最低 0.57
- 委 比 96.28%
- 總股本 2.75万
- 歷史最高 137.25
- 量 比 1.36
- 振 幅 6.25%
- 歷史最低 0.57
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On May 4, 2026, Cit...
05-09 06:05
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international mark...
04-29 20:00
UPDATE: Reported Earlier, Citius Pharma Prices $5M Offering Of 5,076,143 Shares At A Price Of $0.985/Share
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that
04-24 23:44
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.
04-24 22:47
Citius Pharmaceuticals to raise $5M in equity offering
Citius Pharmaceuticals (CTXR) said it entered a definitive agreement to sell about 5.08M shares of common stock, or pre-funded warrants, at $0.985 per share in a registered direct offering priced at t...
04-24 20:20
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares moved upwards by 145.6%...
04-24 20:05
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
Citius Pharmaceuticals ( ($CTXR) ) has issued an announcement. On April 6, 2026...
04-07 05:15
Citius Oncology Provides Commercial Update On U.S. Launch Of LYMPHIR For Treatment Of CTCL, Highlighting Continued Adoption And Advancing Investigator-Led Clinical Studies
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integrationCRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius
03-31 21:14
Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Citius Pharmaceuticals Inc. Announces Annual Stockholders Meeting
Citius Pharmaceuticals Inc. Announces Annual Stockholders Meeting Citius Pharmaceuticals Inc. will hold its annual meeting of stockholders on April 6, 2026, at the company’s headquarters in Cranford, New Jersey. At the meeting, shareholders will vote on the election of seven directors to serve until
02-24 21:01
